Obinutuzumab

Evidence outlook · lead readout

NCT04880863 · Non-small Cell Lung Cancer

The reported results come from study designs that frequently fail to replicate under controlled conditions — see the rationale below.

NCT04880863: The trial enrolled 38 participants in an open-label, single-group design without randomization or a control arm, so its results cannot reliably separate treatment effects from the underlying course of disease. Its primary clinical endpoint, objective response rate, was reported as 15.6% among 32 evaluable participants, but there was no formal between-group comparison.